AsseSSing Impact in pSoriatic Treatment (ASSIST)
How Does PsAID Implementation Affect Treatment Intensification and Patient Satisfaction in PsA
Psoriatic arthritis (PsA) is a form of inflammatory arthritis associated with the skin condition psoriasis. A variety of different treatments are used to try to control arthritis and skin psoriasis and management often involves trial and error to find the right medication for the right person. Very little is known about the decisions made to increase treatment in individual patients. Previous research in rheumatoid arthritis found that clinical measures of disease activity, patient reported outcomes and characteristics of the treating doctor all influenced the decision to change therapy in routine practice.
This investigators particularly want to establish whether routine use of the psoriatic arthritis impact of disease (PsAID-12) questionnaire in the clinic setting can enable a better understanding of the impact of PsA on each individual, improve physician-patient communication and lead to appropriate interventions. The PsAID-12 questionnaire is a relatively new European developed questionnaire measuring patient impact across 12 different domains in PsA.
This study will use routine implementation of the PsAID-12 questionnaire and see if this is related to treatment decisions and patient satisfaction. The investigators will also examine other factors that may influence treatment decisions including patient characteristics, physician characteristics, disease activity and quality of patient-physician interactions.
Studieöversikt
Detaljerad beskrivning
This is an observational, cross-sectional study addressing the factors influencing treatment decisions in patients with PsA. Participants will be treated as usual in their routine clinical practice, but decisions on treatment will be recorded - whether treatment is escalated, unchanged or reduced, and why.
The study will be conducted in 25 rheumatology centres in Europe (UK, France, Germany, Spain and Italy) with five centres in each country. Each participant will only attend for one single study visit which is likely to last around 30 minutes in total. This will be alongside the participant's routine clinic visit. The PsAID-12 questionnaire will be implemented on a tablet computer but the remaining outcomes will be collected on paper CRFs and transferred to a database for analysis.
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Studiekontakt
- Namn: Laura C Coates, MBChB
- Telefonnummer: 07870257823
- E-post: laura.coates@ndorms.ox.ac.uk
Studera Kontakt Backup
- Namn: Jaia Barratt
- Telefonnummer: 02031922074
- E-post: assist@springer.com
Studieorter
-
-
-
Clermont-Ferrand, Frankrike, 63000
- Rekrytering
- CHU Gabriel-Montpied
-
Kontakt:
- Martin Soubrier
- E-post: msoubrier@chu-clermontferrand.fr
-
Le Mans, Frankrike
- Rekrytering
- Centre Hospitalier Le Mans
-
Kontakt:
- Emmanuelle Dernis
- E-post: edernis@ch-lemans.fr
-
Marseille, Frankrike
- Rekrytering
- Hôpitaux Universitaires de Marseille
-
Kontakt:
- Sandrine Guis
- E-post: sandrine.guis@ap-hm.fr
-
Paris, Frankrike, 75651
- Rekrytering
- GERPAL, Hopital de la Pitie
-
Kontakt:
- Laure Gossec
- E-post: laura.gossec@aphp.fr
-
Toulouse, Frankrike
- Rekrytering
- Centre Hospitalier Universitaire (CHU) de Toulouse
-
Kontakt:
- Adeline Ruyssen-Witrand
- E-post: ruyssen-witrand.a@chu-toulouse.fr
-
-
-
-
-
Campobasso, Italien
- Rekrytering
- Ospedale Regionale Cardarelli
-
Kontakt:
- Ennio Lubrano
- E-post: enniolubrano@hotmail.com
-
-
-
-
-
Barcelona, Spanien
- Har inte rekryterat ännu
- Hospital Clinic (Barcelona)
-
Kontakt:
- Julio Ramiez Garcia
- E-post: julramga@gmail.com
-
Coruña, Spanien
- Har inte rekryterat ännu
- Complejo Universitario de a Coruña
-
Kontakt:
- Jose Antonio Pinto
- E-post: jose.antonio.pinto.tasende@sergas.es
-
Madrid, Spanien
- Har inte rekryterat ännu
- Hospital Universitario 12 de Octubre
-
Kontakt:
- Beatriz Joven Ibanez
- E-post: beatrizjoven@hotmail.com
-
Oviedo, Spanien
- Har inte rekryterat ännu
- Hospital Universitario Central de Asturias
-
Kontakt:
- Ruben Queiro
- E-post: rubenque7@yahoo.es
-
Salamanca, Spanien
- Rekrytering
- Hospital Universitario de Salamanca
-
Kontakt:
- Carlos Montilla Morales
- E-post: montillamorales.carlos@gmail.com
-
-
-
-
Greater Manchester
-
Manchester, Greater Manchester, Storbritannien, M13 9WL
- Rekrytering
- Manchester University NHS Foundation Trust
-
Kontakt:
- Pauline Ho
- E-post: pauline.ho@mft.nhs.uk
-
-
Oxfordshire
-
Oxford, Oxfordshire, Storbritannien, OX39DU
- Rekrytering
- Oxford University Hospital NHS Foundation Trust
-
Kontakt:
- Laura C Coates, MBChB
- Telefonnummer: 07870257823
- E-post: laura.coates@ndorms.ox.ac.uk
-
-
Staffordshire
-
Stafford, Staffordshire, Storbritannien, ST16 3SR
- Har inte rekryterat ännu
- Midlands Partnership NHS Foundation Trust
-
Kontakt:
- Jon Packham
- E-post: jon.packham@mpft.nhs.uk
-
-
Wales
-
Cardiff, Wales, Storbritannien, CF14 4HH
- Rekrytering
- Cardiff and vale University LHB
-
Kontakt:
- Ernest Choy
- E-post: choyEH@cardiff.ac.uk
-
-
Yorkshire
-
Bradford, Yorkshire, Storbritannien, BD9 6RJ
- Rekrytering
- Bradford Teaching Hospitals NHS Foundation Trust
-
Kontakt:
- Sarah Twigg
- E-post: sarah.twigg@bthft.nhs.uk
-
-
-
-
-
Bamberg, Tyskland
- Rekrytering
- Klinikum Bamburg
-
Kontakt:
- Axel Hueber
-
Berlin, Tyskland
- Rekrytering
- Rheumatologische Schwerpunktpraxis
-
Kontakt:
- Jan Brandt-Jurgens
-
Frankfurt, Tyskland
- Rekrytering
- Universitätsklinik Frankfurt
-
Kontakt:
- Michaela Kohm
-
Herne, Tyskland
- Rekrytering
- Universitätsklinikum der Ruhr-Universität Bochum
-
Kontakt:
- Uta Kiltz
- E-post: uta.kiltz@elisabethgruppe.de
-
Planegg, Tyskland
- Rekrytering
- MVZ für Rheumatologie Dr. Martin Welcker GmbH
-
Kontakt:
- Martin Welcker
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the study and complete questionnaires in the local language.
- Aged 18 years or above.
- Diagnosed with PsA according to the ClASification of Psoriatic ARthritis (CASPAR) criteria and diagnosis confirmed by a rheumatologist (Taylor 2006).
Exclusion Criteria:
- Patients who don't speak or read the local language
- Patients who are not comfortable filling in an app-based questionnaire or paper CRF.
- Patients with a new diagnosis of PsA at the current clinic visit
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Psoriatic arthritis
Psoriatic arthritis Impact of Disease questionnaires (PsAID) used within routine clinic consultation.
|
PsAID questionnaire
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of patients undergoing treatment escalation
Tidsram: During the consultation (cross sectional study so only one timepoint)
|
Treatment escalation definition includes increase in dose, frequency, change of route, new medication
|
During the consultation (cross sectional study so only one timepoint)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Reduction of therapy
Tidsram: During the consultation (cross sectional study so only one timepoint)
|
Treatment reduction definition includes decrease in dose, frequency, change in route, stopping medication
|
During the consultation (cross sectional study so only one timepoint)
|
|
PsAID-12 scores
Tidsram: During the consultation (cross sectional study so only one timepoint)
|
PsA impact of disease score (scale 0-10 where higher score is worse)
|
During the consultation (cross sectional study so only one timepoint)
|
|
CollaboRATE score
Tidsram: During the consultation (cross sectional study so only one timepoint)
|
Patient satisfaction with consultation (scale 0-9 where higher score is better)
|
During the consultation (cross sectional study so only one timepoint)
|
|
Perceived efficacy on Patient-physician interaction score (PEPPI)
Tidsram: During the consultation (cross sectional study so only one timepoint)
|
Perceived efficacy in consultation (scale 5-25 where higher score is better)
|
During the consultation (cross sectional study so only one timepoint)
|
|
Physicians opinion of how much arthritis is driving treatment decision
Tidsram: During the consultation (cross sectional study so only one timepoint)
|
Visual Analogue Scale 0-10 (scale 0-10 where higher score is worse)
|
During the consultation (cross sectional study so only one timepoint)
|
|
Physicians opinion of how PsAID 12 influenced treatment decision
Tidsram: During the consultation (cross sectional study so only one timepoint)
|
Likert scale 1-5 (scale 0-5 where higher score is worse)
|
During the consultation (cross sectional study so only one timepoint)
|
|
Physicians opinion of how much enthesitis is driving treatment decision
Tidsram: During the consultation (cross sectional study so only one timepoint)
|
Visual Analogue Scale 0-10 (scale 0-10 where higher score is worse)
|
During the consultation (cross sectional study so only one timepoint)
|
|
Physicians opinion of how much psoriasis is driving treatment decision
Tidsram: During the consultation (cross sectional study so only one timepoint)
|
Visual Analogue Scale 0-10 (scale 0-10 where higher score is worse)
|
During the consultation (cross sectional study so only one timepoint)
|
|
Physicians opinion of how much systemic inflammation marker (CRP) is driving treatment decision
Tidsram: During the consultation (cross sectional study so only one timepoint)
|
Visual Analogue Scale 0-10 (scale 0-10 where higher score is worse)
|
During the consultation (cross sectional study so only one timepoint)
|
|
Physicians opinion of how much PROs are driving treatment decision
Tidsram: During the consultation (cross sectional study so only one timepoint)
|
Visual Analogue Scale 0-10 (scale 0-10 where higher score is worse)
|
During the consultation (cross sectional study so only one timepoint)
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 287039
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .